A federal appeals court in the US has declined to overturn an attempt by Novartis to block the launch of a generic version of its blockbuster heart failure drug Entresto. The US Court of Appeals for ...

The generic product is now available nationwide in strengths of 0.3mg, 0.45mg, 0.625mg, 0.9mg, and 1.25mg. The Food and Drug Administration (FDA) has approved the first generic version of Premarin ® ...

A generic drug is a drug that can be manufactured and sold by any company, as long as they meet the stringent criteria for purity as required by Health Canada. It is usually sold under a generic name, ...

The FDA signed off on a second generic option for the abortion pill mifepristone on Tuesday, hours before most of the federal government shut down and despite Republican opposition to the drug. Evita ...

Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk’s injected Saxenda (liraglutide). The compound, ...

Aug 28 (Reuters) - The U.S. Food and Drug Administration has approved Teva Pharmaceuticals' (TEVA.TA), opens new tab cheaper generic version of Novo Nordisk's (NOVOb.CO), opens new tab older ...

Teva's generic Saxenda is the first generic GLP-1 indicated for weight loss. Richardsen added, “This is the fifth first-to-market entry of a Teva generic this year and is an important addition to Teva ...

The Food and Drug Administration sees no difference between brand-name and generic medications for depression. Most psychiatrists readily prescribe generics as effective copies of the original.

A large-scale, real-world analysis of 15,639 patients treated with Collagenase SANTYL Ointment underscores the clinical and economic benefits of early enzymatic debridement in wound management. Using ...

Generic versions of CSL’s iron replacement therapy Venofer have arrived in the U.S. after a yearslong wait. Monday, Viatris and Amphastar Pharmaceuticals both said they have received the FDA’s ...

Novo Nordisk reportedly failed to pay its annual fees to maintain the patent rights in Canada, opening the door to cheaper generic copycats You can save this article by registering for free here. Or ...

Kevin A. Schulman ([email protected]) is a professor of medicine at Stanford University, in Stanford, California. He is a board member and shareholder of Grid Therapeutics (an early stage ...